● Completed

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

Condition: Dry Eye Disease · Sponsor: Instituto Grifols, S.A.

PhasePhase 2

Planned participants103

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a Phase 2, multi-site, double-masked, randomized, vehicle-controlled, study designed to evaluate the safety, tolerability, and efficacy in adult participants with DED.

This description comes directly from the study's public registry record.

Talk to the study team

No contact information is available for this study as per the public registry record.

Always discuss trial participation with your own doctor first.

Locations (10)

GC2302 Study Site 110	Glendale, California, United States	—
GC2302 Study Site 109	Grove, California, United States	—
GC2302 Study Site 103	Newport Beach, California, United States	—
GC2302 Study Site 105	Morrow, Georgia, United States	—
GC2302 Study Site 106	Carmel, Indiana, United States	—
GC2302 Study Site 104	Asheville, North Carolina, United States	—
GC2302 Study Site 101	Garner, North Carolina, United States	—
GC2302 Study Site 107	Cranberry Township, Pennsylvania, United States	—
GC2302 Study Site 102	Memphis, Tennessee, United States	—
GC2302 Study Site 111	San Antonio, Texas, United States	—

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →